journal
https://read.qxmd.com/read/38493789/massive-us-cybersecurity-breach-highlights-perils-of-health-care-consolidation
#1
JOURNAL ARTICLE
Bryant Furlow
No abstract text is available yet for this article.
March 14, 2024: Lancet Oncology
https://read.qxmd.com/read/38467131/activity-of-venetoclax-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukaemia-analysis-of-the-venice-1-multicentre-open-label-single-arm-phase-3b-trial
#2
JOURNAL ARTICLE
Arnon P Kater, Önder Arslan, Fatih Demirkan, Yair Herishanu, Burhan Ferhanoglu, Marcos Gonzalez Diaz, Brian Leber, Marco Montillo, Panayiotis Panayiotidis, Davide Rossi, Alan Skarbnik, Adrian Tempescul, Mehmet Turgut, Clemens H Mellink, Anne-Marie F van der Kevie-Kersemaekers, Stuart Lanham, Ben Sale, Luis Del Rio, Relja Popovic, Brenda J Chyla, Todd Busman, Viktor Komlosi, Xifeng Wang, Kavita Sail, German E Pena, Tamas Vizkelety, Francesco Forconi
BACKGROUND: Most patients with chronic lymphocytic leukaemia progress after treatment or retreatment with targeted therapy or chemoimmunotherapy and have limited subsequent treatment options. Response levels to the single-agent venetoclax in the relapsed setting is unknown. We aimed to assess venetoclax activity in patients with or without previous B-cell receptor-associated kinase inhibitor (BCRi) treatment. METHODS: This multicentre, open-label, single-arm, phase 3b trial (VENICE-1) assessed activity and safety of venetoclax monotherapy in adults with relapsed or refractory chronic lymphocytic leukaemia, stratified by previous exposure to a BCRi...
March 8, 2024: Lancet Oncology
https://read.qxmd.com/read/38461834/alabama-supreme-court-s-extrauterine-children-decision-alarms-oncologists-and-fertility-experts
#3
JOURNAL ARTICLE
Bryant Furlow
No abstract text is available yet for this article.
March 7, 2024: Lancet Oncology
https://read.qxmd.com/read/38461833/innovation-in-gynaecological-cancer-highlighting-global-disparities
#4
JOURNAL ARTICLE
Maria Kyrgiou, Sarah Bowden, Lynette Denny, Anna Fagotti, Nadim R Abu-Rustum, Pedro T Ramirez, Denis Querleu
No abstract text is available yet for this article.
March 7, 2024: Lancet Oncology
https://read.qxmd.com/read/38461832/non-communicable-diseases-in-humanitarian-settings
#5
JOURNAL ARTICLE
Talha Burki
No abstract text is available yet for this article.
March 7, 2024: Lancet Oncology
https://read.qxmd.com/read/38458207/correlations-of-response-rate-and-progression-free-survival-with-overall-survival-in-immunotherapy-trials-for-metastatic-non-small-cell-lung-cancer-an-fda-pooled-analysis
#6
JOURNAL ARTICLE
Bernardo Haddock Lobo Goulart, Sirisha L Mushti, Somak Chatterjee, Erin Larkins, Pallavi S Mishra-Kalyani, Richard Pazdur, Paul G Kluetz, Harpreet Singh
BACKGROUND: Radiographic changes might not fully capture the treatment effects of immune checkpoint inhibitors (ICIs). We aimed to assess correlations of overall response rate and progression-free survival with overall survival in trials of ICIs for metastatic non-small-cell lung cancer (NSCLC). METHODS: To assess trial-level and patient-level correlations of overall response rate and progression-free survival with overall survival, we conducted a pooled analysis of first-line randomised trials (including patients aged ≥18 years with metastatic squamous and non-squamous NSCLC and an Eastern Cooperative Oncology Group performance status of 0-1) submitted to the US Food and Drug Administration from June 24, 2016, to March 16, 2021...
March 5, 2024: Lancet Oncology
https://read.qxmd.com/read/38432235/indonesia-and-the-philippines-take-steps-to-control-cancer
#7
JOURNAL ARTICLE
Manjulika Das
No abstract text is available yet for this article.
February 29, 2024: Lancet Oncology
https://read.qxmd.com/read/38423030/-68-ga-rm2-pet-mri-versus-mri-alone-for-evaluation-of-patients-with-biochemical-recurrence-of-prostate-cancer-a-single-centre-single-arm-phase-2-3-imaging-trial
#8
JOURNAL ARTICLE
Heying Duan, Farshad Moradi, Guido A Davidzon, Tie Liang, Hong Song, Andreas M Loening, Shreyas Vasanawala, Sandy Srinivas, James D Brooks, Steven Hancock, Andrei Iagaru
BACKGROUND: National Comprehensive Cancer Network guidelines include prostate-specific membrane antigen (PSMA)-targeted PET for detection of biochemical recurrence of prostate cancer. However, targeting a single tumour characteristic might not be sufficient to reflect the full extent of disease. Gastrin releasing peptide receptors (GRPR) have been shown to be overexpressed in prostate cancer. In this study, we aimed to evaluate the diagnostic performance of the GRPR-targeting radiopharmaceutical 68 Ga-RM2 in patients with biochemical recurrence of prostate cancer...
February 26, 2024: Lancet Oncology
https://read.qxmd.com/read/38408465/towards-world-class-radiotherapy-in-the-uk-time-for-transformation
#9
JOURNAL ARTICLE
Katie Wakeham, Tim Cooper, Carl Rowbottom, Anthony J Chalmers, Pat Price, Sarah Quinlan, Katie Spencer
No abstract text is available yet for this article.
February 23, 2024: Lancet Oncology
https://read.qxmd.com/read/38402893/south-africa-combats-gaps-in-cancer-data
#10
JOURNAL ARTICLE
Manjulika Das
No abstract text is available yet for this article.
February 22, 2024: Lancet Oncology
https://read.qxmd.com/read/38368897/children-and-young-people-cancer-taskforce
#11
JOURNAL ARTICLE
Talha Burki
No abstract text is available yet for this article.
February 15, 2024: Lancet Oncology
https://read.qxmd.com/read/38346438/the-multitarget-faecal-immunochemical-test-for-improving-stool-based-colorectal-cancer-screening-programmes-a-dutch-population-based-paired-design-intervention-study
#12
JOURNAL ARTICLE
Pieter H A Wisse, Willemijn de Klaver, Francine van Wifferen, Frejanne G van Maaren-Meijer, Huub E van Ingen, Lana Meiqari, Iris Huitink, Mariska Bierkens, Margriet Lemmens, Marjolein J E Greuter, Monique E van Leerdam, Manon C W Spaander, Evelien Dekker, Veerle M H Coupé, Beatriz Carvalho, Meike de Wit, Gerrit A Meijer
BACKGROUND: The faecal immunochemical test (FIT) is widely employed for colorectal cancer screening. However, its sensitivity for advanced precursor lesions remains suboptimal. The multitarget FIT (mtFIT), measuring haemoglobin, calprotectin, and serpin family F member 2, has demonstrated enhanced sensitivity for advanced neoplasia, especially advanced adenomas, at equal specificity to FIT. This study aimed to prospectively validate and investigate the clinical utlitity of mtFIT versus FIT in a setting of population-based colorectal cancer screening...
February 9, 2024: Lancet Oncology
https://read.qxmd.com/read/38342115/activity-and-safety-of-enobosarm-a-novel-oral-selective-androgen-receptor-modulator-in-androgen-receptor-positive-oestrogen-receptor-positive-and-her2-negative-advanced-breast-cancer-study-g200802-a-randomised-open-label-multicentre-multinational-parallel-design
#13
JOURNAL ARTICLE
Carlo Palmieri, Hannah Linden, Stephen N Birrell, Sally Wheelwright, Elgene Lim, Lee S Schwartzberg, Amy R Dwyer, Theresa E Hickey, Hope S Rugo, Patrick Cobb, Joyce A O'Shaughnessy, Stephen Johnston, Adam Brufsky, Wayne D Tilley, Beth Overmoyer
BACKGROUND: The androgen receptor is a tumour suppressor in oestrogen receptor-positive breast cancer. The activity and safety of enobosarm, an oral selective androgen receptor modulator, was evaluated in women with oestrogen receptor (ER)-positive, HER2-negative, and androgen receptor (AR)-positive disease. METHODS: Women who were postmenopausal (aged ≥18 years) with previously treated ER-positive, HER2-negative, locally advanced or metastatic breast cancer with an Eastern Cooperative Oncology Group performance status of 0-2 were enrolled in a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial done at 35 cancer treatment centres in nine countries...
February 8, 2024: Lancet Oncology
https://read.qxmd.com/read/38342113/brca-testing-launched-for-people-of-jewish-ancestry-in-england
#14
JOURNAL ARTICLE
Priya Venkatesan
No abstract text is available yet for this article.
February 8, 2024: Lancet Oncology
https://read.qxmd.com/read/38342112/androgen-receptor-agonism-in-advanced-oestrogen-receptor-positive-breast-cancer
#15
JOURNAL ARTICLE
Nan Chen, Rita Nanda
No abstract text is available yet for this article.
February 8, 2024: Lancet Oncology
https://read.qxmd.com/read/38310913/hpv-vaccination-programme-success-in-scotland
#16
JOURNAL ARTICLE
Talha Burki
No abstract text is available yet for this article.
February 1, 2024: Lancet Oncology
https://read.qxmd.com/read/38310912/iaea-site-visit-to-the-zaporizhzhya-nuclear-power-plant-in-ukraine
#17
JOURNAL ARTICLE
Manjulika Das
No abstract text is available yet for this article.
March 2024: Lancet Oncology
https://read.qxmd.com/read/38309282/tabelecleucel-for-allogeneic-haematopoietic-stem-cell-or-solid-organ-transplant-recipients-with-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-after-failure-of-rituximab-or-rituximab-and-chemotherapy-allele-a-phase-3-multicentre-open
#18
JOURNAL ARTICLE
Kris Michael Mahadeo, Robert Baiocchi, Amer Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Xinyuan Duan, Laurence Gamelin, Armin Ghobadi, Norma Guzman-Becerra, Manher Joshi, Aditi Mehta, Willis H Navarro, Sarah Nikiforow, Richard J O'Reilly, Ran Reshef, Fiona Ruiz, Tassja Spindler, Susan Prockop
BACKGROUND: Survival in Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease following haematopoietic stem-cell transplant (HSCT) or solid organ transplant (SOT) is poor after failure of initial therapy, indicating an urgent need for therapies for this ultra-rare disease. With recent EU marketing authorisation, tabelecleucel is the first off-the-shelf, allogeneic, EBV-specific T-cell immunotherapy to receive approval for treatment of relapsed or refractory EBV-positive post-transplant lymphoproliferative disease...
January 31, 2024: Lancet Oncology
https://read.qxmd.com/read/38307103/strategies-to-promote-sustainable-care-for-children-with-cancer-in-ukraine
#19
JOURNAL ARTICLE
Asya Agulnik, Yuliya Nogovitsyna, Roman Kizyma, Taisiya Yakimkova, Victoria Vivtcharenko, Nickhill Bhakta, Paul H Wise, Carlos Rodriguez-Galindo, Arman Kacharian
No abstract text is available yet for this article.
January 30, 2024: Lancet Oncology
https://read.qxmd.com/read/38307102/complete-cancer-prevalence-in-europe-in-2020-by-disease-duration-and-country-eurocare-6-a-population-based-study
#20
JOURNAL ARTICLE
Roberta De Angelis, Elena Demuru, Paolo Baili, Xavier Troussard, Alexander Katalinic, Maria Dolores Chirlaque Lopez, Kaire Innos, Mariano Santaquilani, Marcel Blum, Leonardo Ventura, Keiu Paapsi, Rocco Galasso, Marcela Guevara, Giorgia Randi, Manola Bettio, Laura Botta, Stefano Guzzinati, Luigino Dal Maso, Silvia Rossi
BACKGROUND: Cancer survivors-people living with and beyond cancer-are a growing population with different health needs depending on prognosis and time since diagnosis. Despite being increasingly necessary, complete information on cancer prevalence is not systematically available in all European countries. We aimed to fill this gap by analysing population-based cancer registry data from the EUROCARE-6 study. METHODS: In this population-based study, using incidence and follow-up data up to Jan 1, 2013, from 61 cancer registries, complete and limited-duration prevalence by cancer type, sex, and age were estimated for 29 European countries and the 27 countries in the EU (EU27; represented by 22 member states that contributed registry data) using the completeness index method...
January 30, 2024: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.